Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-636-9 | CAS number: 108-99-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
This substance, along with other pyridines of similar structure, has moderate acute oral, dermal and inhalation toxicity.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1983
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Well conducted study similar to OECD 401 protocol. The study was done prior to implementation of GLPs.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- 320, 630, 1,300, 2,000, 3,200, 5,000 mg/kg
- No. of animals per sex per dose:
- 3
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Daily
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, other: Clinical signs - Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 630 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 320 mg/kg - 0/3
630 mg/kg - 1/3
1,300 mg/kg - 3/3
2,000 mg/kg - 3/3
3,200 mg/kg - 3/3
5,000 mg/kg - 3/3 - Clinical signs:
- other: 320 mg/kg = lethargy and watery eyes 630, 1,300 and 2,000 mg/kg = lethargy, watery eyes, loss of motor coordination, excessive salivation, rapid shallow breathing and unconsciousness 3,200 mg/kg = watery eyes, excessive salivation, rapid shallow breathing
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information meets criteria of 300 mg/kg bw < LD50 < 2000 mg/kg bw. Criteria used for interpretation of results: EU
- Conclusions:
- The oral LD50 of b-picoline in male Fisher rats was approximately 630 mg/kg. This meets the criteria for classification as Category 4 according to Regulation EC No. 1272/2008.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 630 mg/kg bw
- Quality of whole database:
- adequate
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Reliable with restrictions; acceptable, well-documented publication/study report which meets basic scientific principles.
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Rats were exposed (nose-only) to vapours of test material for a single 4 hour period. Clinical signs were note. Lethality and weight gain was followed for 14 days after exposure to determine levels associated with acute lethality.
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- Rats were 8 weeks of age, weighing between 237 and 279 g.
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- nose only
- Vehicle:
- not specified
- Analytical verification of test atmosphere concentrations:
- yes
- Remarks:
- gas chromatography
- Duration of exposure:
- 4 h
- Concentrations:
- 1300 and 3300 ppm, equivalent to about 5000 mg/m3 and 12,500 mg/m3, respectively
- No. of animals per sex per dose:
- 6 rats/sex/group
- Control animals:
- no
- Details on study design:
- Rats were weighed prior to exposure and observed during exposure. Surviving rats were weighed and observed daily for 14 days post exposure, weekends excluded except when deemed necessary by the rats’ condition. Except during exposure, feed and water were available ad libitum.
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- > 1 300 - < 3 300 ppm
- Based on:
- test mat.
- Exp. duration:
- 4 h
- Remarks on result:
- other: Deaths at 1300 ppm: 0/6, Deaths at 3300 ppm: 6/6.
- Mortality:
- Deaths at 1300 ppm: 0/6,
Deaths at 3300 ppm: 6/6. - Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information 2500 < LC50 <10000 ppm. Criteria used for interpretation of results: EU
- Conclusions:
- The lethality of inhalation exposure to 3-picoline (3-methylpyridine) was investigated in male rats. The LC50 was between 1300 ppm and 3300 ppm, which spans 2 hazard categories. No deaths were observed at the low concentration of 1300 ppm. A middle value of 2500 ppm is chosen as the LD50, equivalent to 9521 mg/m3 or 9.5 mg/L, which is at the threshold between two classification categories. Considering the consistent behaviour of this substance with other category members, and the fact that two other category members show inhalation lethality at ranges above 10 mg/L, this substance is placed in GHS category 4.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 9 521 mg/m³ air
- Quality of whole database:
- adequate
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1983
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Well-conducted study similar to OECD 402 protocol.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- not specified
- Type of coverage:
- not specified
- Vehicle:
- unchanged (no vehicle)
- Duration of exposure:
- 24 Hours
- Doses:
- 200, 800, 2000 mg/kg
- No. of animals per sex per dose:
- 2/dose
- Control animals:
- not specified
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations - daily
- Necropsy of survivors performed: no
- Other examinations performed: clinical signs, body weight - Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- > 800 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 200 mg/kg -0/2
800 mg/kg - 0/2
2,000 mg/kg - 2/2 - Clinical signs:
- other: 200 mg/kg - lethargy 800 mg/kg - lethargy, apparent loss of appetite and semi-consciousness 2,000 mg/kg - semi-consciousness, watery eyes and rapid shallow breathing
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Meets criteria of 300 mg/kg bw < LD50 < 2000 mg/kg bw. Criteria used for interpretation of results: EU
- Conclusions:
- The dermal LD50 of b-picoline in rabbits was > 800 and < 2000 mg/kg bw. The substance is classified as Category 4 according to Regulation EC No. 1272/2008.
Reference
Moderate redness, slight to moderate swelling and moderate necrosis were observed on the application sites of surviving rabbits 24 hours post exposure.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 1 000 mg/kg bw
- Quality of whole database:
- adequate
Additional information
The acute oral toxicity LD50 value for 3-methylpyridine is 630 mg/kg bw. The acute inhalation LD50 is greater than 1300 but less than 3300 ppm, and the value of 2500 ppm is selected as a midpoint value. This corresponds to an LC50 of 9521 mg/m3.
The acute dermal LD50 is greater than 400 mg/kg bw, a value where there were no deaths among 5 exposed rats (Oley, 2008). The value selected for the dermal LD50 is 1000 mg/kg bw, based on the findings in rabbits of Fitzgerald et.al, 1991, where the LD50 was less than 1000 mg/kg bw, and Carreon, 1982, where the LD50 in rabbits was > 1000 and < 2000 mg/kg bw.Justification for selection of acute toxicity – oral endpoint
Experimental value
Justification for selection of acute toxicity – inhalation endpoint
Experimental value
Justification for selection of acute toxicity – dermal endpoint
experimental value in rabbits
Justification for classification or non-classification
3 -Methylpyridine shows acute toxicity LD50 values of 630 mg/kg via the oral route, placing it in Category 4 (between 300 and 2000 mg/kg). For the inhalation route, the LC50 is 2500 ppm or 9.52 mg/L (9521 mg/m3), at the threshold between two categories. Considering that other members of the chemical category (pyridine, 2 -methylpyridine and 4 -methylpyridine) show LC50 values of generally greater than 10, this substance is also placed in Category 4 (between 2500 and 20000 ppm or 10 -20 mg/L). Lastly, the dermal LD50 is greater than 400 mg/kg in rats. A value of 1000 mg/kg bw has been selected as the most appropriate single value based on experimental data in rabbits, placing the substance in Category 3. These classifications are comparable to or more conservative than those for the other members of the pyridine and methylpyridine category, according to Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.